Cisapride 20 mg b.d. For preventing symptoms of GERD induced by a provocative meal

被引:8
作者
Castell, D
Silvers, D
Littlejohn, T
Orr, W
Napolitano, J
Oleka, N
Jokubaitis, L
机构
[1] Allegheny Univ Hosp, Philadelphia, PA USA
[2] Drug Res Serv Inc, Metairie, LA USA
[3] Piedmont Med Res Associates, Winston Salem, NC USA
[4] Lynn Inst Hlth Care Res, Oklahoma City, OK USA
[5] Janssen Res Fdn, Titusville, NJ USA
关键词
D O I
10.1046/j.1365-2036.1999.00525.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Cisapride is a substituted piperidinyl benzamide indicated for the symptomatic treatment of patients with nocturnal heartburn due to gastrooesophageal reflux disease (GERD). The currently recommended dosing regimen for cisapride is 10 mg q.d.s., but the elimination half-life of 8-10 h supports b.d. dosing with 20 mg. Methods: This multicentre, randomized, double-blind, placebo-controlled trial was undertaken to determine the efficacy and safety of cisapride 20 mg b.d. dosing in reducing or preventing heartburn and other meal-related symptoms after challenge with a provocative fatty meal. In phase 1 of the study, 137 patients with at least a 3-month history of symptoms suggestive of GERD and at least five episodes of GERD on 7-day diary were eligible to receive single-blind treatment with placebo for 7 (range +/-3) days and then ingested a provocative meal. One hundred and twenty-two patients (45 men and 77 women, 22-65 years of age) who experienced heartburn during the 3 h after ingestion of the meal qualified for the double-blind phase of the study and were randomly assigned to either cisapride 20 mg or matching placebo b.d. for 7 (+/-3) days. At the end of this period, 118 patients again ate a fatty meal and were assessed for symptoms of GERD. Results: Heartburn was prevented in a significantly higher percentage of cisapride-treated patients (40%; 24 out of 60) than placebo-treated patients (21%; 12 out of 58) after the repeat provocative meal at the end of the double-blind phase (P = 0.017). Cisapride was also significantly more effective in reducing the severity of postprandial heartburn, belching, and regurgitation (P < 0.05). Twice-daily dosing with cisapride 20 mg was well tolerated; the number of cisapride- and placebo-treated patients who experienced at least one adverse event was similar (31% and 22%, respectively). The most common adverse events were diarrhoea (cisapride, 18%; placebo, 0%) and rhinitis (cisapride, 2%; placebo, 5%). Conclusions: These results demonstrate that cisapride 20 mg b.d. is effective in preventing or reducing symptoms of heartburn in patients who developed heartburn after ingesting a provocative fatty meal. Cisapride was also effective in reducing the severity of heartburn-related symptoms such as belching and regurgitation.
引用
收藏
页码:787 / 794
页数:8
相关论文
共 22 条
[1]  
BECKER DJ, 1989, AM J GASTROENTEROL, V84, P782
[2]   EFFECT OF CISAPRIDE ON RELAPSE OF ESOPHAGITIS - A MULTINATIONAL, PLACEBO-CONTROLLED TRIAL IN PATIENTS HEALED WITH AN ANTISECRETORY DRUG [J].
BLUM, AL ;
ADAMI, B ;
BOUZO, MH ;
BRANDSTATTER, G ;
FUMAGALLI, I ;
GALMICHE, JP ;
HEBBELN, H ;
HENTSCHEL, E ;
HUTTEMANN, W ;
SCHUTZ, E ;
VERLINDEN, M .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (03) :551-560
[3]   DETECTION METHODS AND STRATEGIES FOR IMPROVING MEDICATION COMPLIANCE [J].
BOND, WS ;
HUSSAR, DA .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1991, 48 (09) :1978-1988
[4]   Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care [J].
Brunner, H .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (04) :587-594
[5]  
Castell D, 1997, GASTROENTEROLOGY, V112, pA84
[6]  
CHAMPION MC, 1994, CONSULTANT PHARM SA, P14
[7]   HOW OFTEN IS MEDICATION TAKEN AS PRESCRIBED - A NOVEL ASSESSMENT TECHNIQUE [J].
CRAMER, JA ;
MATTSON, RH ;
PREVEY, ML ;
SCHEYER, RD ;
OUELLETTE, VL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (22) :3273-3277
[8]  
DENT J, 1992, GASTROINTESTINAL DYS, P127
[9]  
GELDOF H, 1993, ALIMENT PHARM THERAP, V7, P409
[10]  
GREENBERG RN, 1984, CLIN THER, V6, P592